Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Bridging laboratory assays, genetics, and clinical phenotypes in antithrombin deficiency : rethinking the diagnostic paradigm
Avtorji:ID Rojnik, Tamara (Avtor)
ID Šket, Robert (Avtor)
ID Slapnik, Barbara (Avtor)
ID Vrhovšek, Blaž (Avtor)
ID Mavri, Alenka (Avtor)
ID Debeljak, Maruša (Avtor)
ID Božič Mijovski, Mojca (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (3,15 MB)
MD5: 3938E6B820AC81A4E7374FB040EB0400
 
URL URL - Izvorni URL, za dostop obiščite https://www.thrombosisresearch.com/article/S0049-3848(26)00108-8/fulltext
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Background Diagnosis of antithrombin deficiency (ATD), the most severe inherited thrombophilia, commonly relies on functional assays despite their uncertain sensitivity. Moreover, routine characterization of ATD remains uncommon due to limited supporting clinical data. Objectives This study aimed to evaluate the diagnostic sensitivity of commercial antithrombin (AT) activity assays and assess clinical differences among ATD types to refine the current diagnostic approach. Methods Eighty-eight patients with decreased AT activity and 124 consecutive patients with unprovoked venous thromboembolism were included. AT activity was measured using six assays. Genetic analysis of SERPINC1 was performed by Sanger sequencing and multiplex ligation-dependent probe amplification; additionally, long-read whole-genome sequencing was conducted. Results Fifteen SERPINC1 variants were detected, including two novel ones. AT Padua I (p.Arg79His) was the most prevalent (49%). Sensitivity varied across AT activity assays, particularly for types IIRS and IIHBS, with variant-specific discrepancies. AT Dublin (p.Val30Glu), causing transient deficiency, was undetected by all assays. Two assays demonstrated very high sensitivity (93%; p < 0.001), while two others showed poor sensitivity (46%). Regardless of measured AT activity, characterization of ATD type enabled better risk stratification. Type I was associated with early-onset and recurrent venous thromboembolism, and type IIHBS was distinctly linked to arterial thrombosis. Conclusions Assay sensitivity varies considerably, and only a few proved suitable as first-line tests. Genetic testing for common variants undetectable by even the most sensitive assays, along with ATD characterization, should be integrated into diagnostic algorithms. Our results also suggest that young patients with arterial thrombosis should be screened for ATD.
Ključne besede:antithrombin iii deficiency, blood coagulation tests, mutation, thrombophilia
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2026
Št. strani:str. 1-10
Številčenje:Vol. 261, [article no.] 109689
PID:20.500.12556/DiRROS-31250 Novo okno
UDK:61
ISSN pri članku:1879-2472
DOI:10.1016/j.thromres.2026.109689 Novo okno
COBISS.SI-ID:281250819 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 11. 6. 2026;
Datum objave v DiRROS:23.07.2026
Število ogledov:77
Število prenosov:60
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Thrombosis Research
Založnik:Pergamon
COBISS.SI-ID:23047685 Novo okno

Gradivo je financirano iz projekta

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Department of Vascular Diseases, University Medical Centre Ljubljan
Številka projekta:/
Naslov:/
Akronim:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:University Children's Hospital, University Medical Centre Ljubljana
Številka projekta:/
Naslov:/

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj